Comparing the current results to its competitors, Prenetics Global Limited reported Revenue increase in the 4 quarter 2025 by 201.94 % year on year. The sales growth was above Prenetics Global Limited's competitors' average revenue growth of 15.63 %, achieved in the same quarter.
Prenetics Global Limited, despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 188.83 %
Prenetics Global Limited's Comment on Competition and Industry Peers
The company operates its consumer genetic testing business primarily through its CircleDNA product line in a highly competitive market with established competitors possessing stronger marketing capabilities and greater financial resources. The nutrient product market, where the company markets its IM8 brand, is also competitive, with established competitors potentially introducing similar or superior products. The company's success in these markets depends on effective marketing and public perception. The development of the IM8 business involves significant upfront costs related to marketing, research and development, and distribution, which may strain financial and operational resources. Failure to meet revenue expectations could result in financial losses and affect long-term success.
Due to outstanding performance in Overall company, revenue grew by 201.94 % Prenetics Global Limited improved its market share, to approximately 2.72 %.
January 21, 2025
In an era where health and wellness trends are constantly evolving, Prenetics is making a bold statement with its latest offering, the IM8, a comprehensive health solution making its debut in the United States. Co-founded by soccer legend and global icon David Beckham, the IM8 aims to revolutionize how consumers approach their foundational health.The exciting launch, held in Los Angeles, saw Beckham share the stage with a world-class scientific team, underscoring the product s commitment to combining cutting-edge science with accessible health solutions for the everyday consumer. “IM8 is not just about tracking your health; it s about understanding it fundamentally,” Beckham expressed at the event. “We...
July 11, 2024
Prenetics Partners with David Beckham to Launch New Health and Wellness Brand LOS ANGELES, July 11, 2024 Prenetics (NASDAQ: PRE), a prominent company in the health sciences sector, has announced a strategic partnership with former international footballer David Beckham. Beckham, who is also recognized for his entrepreneurial efforts and philanthropy, has become a strategic investor in Prenetics and will collaborate on a new health and wellness brand named IM8.The partnership aims to develop innovative consumer health products under the IM8 brand, although specific details of the upcoming products have yet to be disclosed. By combining Prenetics expertise in health sciences with Beckham s global influenc...
June 17, 2024
Prenetics Sets Promising Path for Growth and Shareholder ValueIn a recent move to bolster investor relations and shareholder communications, Prenetics, a leading global genetics and digital health company, has tapped MZ Group as its strategic partner. As Prenetics gears up for future growth, this alliance aims to emphasize the company s impressive cash position, debt-free status, and its strong management team s commitment to delivering value to its shareholders.With an unwavering focus on innovation and technology, Prenetics has firmly established itself in the genetics and digital health industry. By utilizing cutting-edge solutions, the company offers personalized and actionable insights to individuals, e...
February 9, 2024
Prenetics: Pioneering Genetic Research on the International Space StationIn a groundbreaking move, genetic testing company Prenetics has announced a strategic investment and a five-year research collaboration with Metavisionaries to pioneer research and development (RandD) on the International Space Station (ISS). This bold initiative marks a significant step forward in space exploration and deepens the integration of cutting-edge technology in the field of genetics.The Memorandum of Understanding (MOU) was signed in a momentous ceremony in Dubai, attended by esteemed individuals from both Prenetics and Metavisionaries, as well as representatives from the UAE Space Agency. Dr. Ghada Alsaleh, Sonia Pawelczyk,...
Illumina Inc is a leading company in the genomics sector, focusing on next-generation sequencing technologies that enhance genetic analysis. Their business model encompasses a diverse range of products, including sequencing platforms, reagents, and bioinformatics solutions, which together facilitate comprehensive genomic studies for researchers. By integrating these tools, Illumina supports advancements in fields such as oncology, drug discovery, and personalized healthcare, positioning itself at the forefront of genomic innovation.
Caredx Inc is a precision medicine company with a business model focused on transplant diagnostics. They develop and commercialize non-invasive tests to identify and monitor organ transplant rejection. By offering innovative solutions and services in the transplant field, Caredx Inc aims to improve outcomes for patients and provide healthcare professionals with valuable information to guide treatment decisions.
Fulgent Genetics Inc is a genetic testing company that offers comprehensive, flexible, and affordable genetic testing solutions for various applications, including clinical diagnostics, carrier screening, and genetic research.
Guardant Health Inc's business model revolves around providing advanced genomic testing services for cancer patients. It specializes in developing liquid biopsy tests that analyze circulating tumor DNA (ctDNA) in the blood. These tests help in early cancer detection, treatment selection, and monitoring of cancer progression. Guardant Health Inc collaborates with healthcare providers, pharmaceutical companies, and researchers to provide these innovative tests and contribute to the advancement of precision medicine in oncology.
23andMe Holding Co operates as a direct-to-consumer genetic testing company. Their business model primarily revolves around selling DNA testing kits to individuals, who can then provide a saliva sample and receive reports on their genetic ancestry, health predispositions, and other genetic traits. The company generates revenue by charging customers for the testing kits, as well as offering additional subscription-based services for ongoing access to updated reports and insights.
Sources:
Prenetics Global Limited’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Prenetics Global Limited versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
